Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Alopecia Induced by Dopamine Agonists
Neurol 58:829-830, Tabamo,R.E. &Di Rocco,A., 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978